Pharma cos eye buyouts in US, Europe
Strong earnings and a weak dollar could prompt Indian drug makers to look carefully at the US and European pharma space as the markets there looks ripe for acquisition. According to Bradford Crutchfield, VP, Bio-Rad Laboratories USA, it is a great time for Indian companies to look at the US and Europe especially for niche segments which they might not be good at.
